Overview

Evaluation of the Efficacy of Fomepizole in the Treatment of Acetaminophen Overdose

Status:
Not yet recruiting
Trial end date:
2025-11-30
Target enrollment:
Participant gender:
Summary
This study is a randomized, placebo-controlled double-blinded clinical trial of patients presenting with acetaminophen poisoning who are at increased risk of developing liver injury. With this trial the investigators are hoping to show the superiority of acetylcysteine (NAC) + fomepizole (4-MP) compared to treatment with acetylcysteine alone. The primary objective of this trial is to determine the effect of fomepizole on the severity of acute liver injury in patients with acetaminophen poisoning.
Phase:
Phase 2
Details
Lead Sponsor:
Richard Dart, MD, PhD
Collaborator:
Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division
Treatments:
Acetylcysteine
Fomepizole
N-monoacetylcystine